The deal will significantly expand iNova's portfolio of consumer health products and add substantial new sales in high-growth markets, said the spokesperson.
Following the deal, iNova’s consumer health product portfolio will account for over 80% of its total product sales, with Asia as the largest region in terms of sales, representing around 35% of the company's revenue, the company said. “This acquisition transforms the scale of iNova and accelerates our market expansion to high-growth markets in Asia and the Middle East,” said Dan Spira, CEO of iNova, in a statement on Monday.
INova, which dates back to 1846 according to its website, primarily sells cough and cold, throat, skin care and natural health drugs and products.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: